Purpose: The introduction of tyrosine kinase inhibitors has transformed the care of patients with chronic myeloid leukemia, with survival approaching that of healthy individuals. Current-day challenges in chronic myeloid leukemia care include adherence to tyrosine kinase inhibitor therapy. We studied adherence from resource-constrained settings and tried to analyze the factors responsible for nonadherence in these individuals. We also correlated adherence to current molecular status. Patients and Methods: This was a single-center, cross-sectional, observational study from north India. It consisted of a questionnaire-based survey in which a one-to-one interview technique was used by trained nursing staff administering the Modified Morisky Ad...
CONTEXT: Worldwide, chronic myeloid leukemia (CML) accounts for 15% of all leukemia types. CML treat...
University of Medicine and Pharmacy, Targu Mures, Romania, The 6th International Medical Congress fo...
Imatinib mesylate is currently the standard therapy for chronic myelogenous leukemia patients Despit...
BACKGROUND: Optimal adherence to imatinib therapy is of paramount importance to maximise treatment...
Adherence to imatinib(IM) is of utmost importance in patients with chronic myeloid leukemia(CML) to ...
Objective: To assess the level of adherence to treatment with imatinib in patients with chronic myel...
Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic mye...
The introduction of oral tyrosine kinase inhibitors (TKIs) has dramatically improved outcomes in chr...
Abstract. Adherence to imatinib(IM) is of utmost importance in patients with chronic myeloid leukemi...
BCR-ABL inhibitors for treating chronic myeloid leukemia in chronic phase have transformed a previou...
Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic mye...
Background: Two recent studies have identified a strong association between treatment adherence and ...
Background: Despite the revolutionary success of introducing tyrosine kinase inhibitors (TKIs), such...
Objective: Consistent use of imatinib is critical for treatment success in chronic myeloid leukemia,...
BACKGROUND: Despite the revolutionary success of introducing tyrosine kinase inhibitors (TKIs), suc...
CONTEXT: Worldwide, chronic myeloid leukemia (CML) accounts for 15% of all leukemia types. CML treat...
University of Medicine and Pharmacy, Targu Mures, Romania, The 6th International Medical Congress fo...
Imatinib mesylate is currently the standard therapy for chronic myelogenous leukemia patients Despit...
BACKGROUND: Optimal adherence to imatinib therapy is of paramount importance to maximise treatment...
Adherence to imatinib(IM) is of utmost importance in patients with chronic myeloid leukemia(CML) to ...
Objective: To assess the level of adherence to treatment with imatinib in patients with chronic myel...
Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic mye...
The introduction of oral tyrosine kinase inhibitors (TKIs) has dramatically improved outcomes in chr...
Abstract. Adherence to imatinib(IM) is of utmost importance in patients with chronic myeloid leukemi...
BCR-ABL inhibitors for treating chronic myeloid leukemia in chronic phase have transformed a previou...
Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic mye...
Background: Two recent studies have identified a strong association between treatment adherence and ...
Background: Despite the revolutionary success of introducing tyrosine kinase inhibitors (TKIs), such...
Objective: Consistent use of imatinib is critical for treatment success in chronic myeloid leukemia,...
BACKGROUND: Despite the revolutionary success of introducing tyrosine kinase inhibitors (TKIs), suc...
CONTEXT: Worldwide, chronic myeloid leukemia (CML) accounts for 15% of all leukemia types. CML treat...
University of Medicine and Pharmacy, Targu Mures, Romania, The 6th International Medical Congress fo...
Imatinib mesylate is currently the standard therapy for chronic myelogenous leukemia patients Despit...